Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer.
We report our experience in neoadjuvant breast cancer chemotherapy in a single centre between 2000 and 2011. We looked for predictive factors for response to neoadjuvant chemotherapy in the present study. A total of 110 consecutive breast cancer patients were treated with neoadjuvant chemotherapy in our centre. Pathological response was achieved in 24 HR+/HER2- (38.7%), 25 HER2+ (67.6%) and five triple-negative (45.5%) (p = 0.02) patients. No statistically significant differences were found in pathological tumour response according to T stage. The multivariate analysis revealed tumour subtype was the only associated factor for pathological response, with HER2 + tumours the best responders, OR 3.9 (1.5-9.9): 5-year DFS was 40% HER2+/no response; 78% HER2+/response; 65% HR+/HER2-/no response; 82% HR+/HER2-/response; 25% triple-negative/no response and 100% triple-negative/response. HR and HER2 status were the only prognostic factors for pathological response. pCR was correlated with survival in all tumour subtypes.
a Gynecologic Oncology and Breast Pathology Section, Hospital Universitari Quirón Dexeus , Barcelona , Spain.
S
S
Baulies
a Gynecologic Oncology and Breast Pathology Section, Hospital Universitari Quirón Dexeus , Barcelona , Spain.
M
M
Cusidó
b Department of Medical Oncology , Hospital Universitari Quirón Dexeus , Barcelona , Spain.
M
M
González-Cao
c Department of Pathology , Hospital Universitari Quirón Dexeus , Barcelona , Spain.
F
F
Tresserra
a Gynecologic Oncology and Breast Pathology Section, Hospital Universitari Quirón Dexeus , Barcelona , Spain.
F
F
Fargas
d Statistics and Epidemiology Unit, Hospital Universitari Quirón Dexeus , Barcelona , Spain.
I
I
Rodríguez
e Gynecologic Diagnostic Imaging, Department of Obstetrics , Gynecology and Human Reproduction, Hospital Universitari Quirón Dexeus , Barcelona , Spain.
B
B
Úbeda
a Gynecologic Oncology and Breast Pathology Section, Hospital Universitari Quirón Dexeus , Barcelona , Spain.
C
C
Ara
a Gynecologic Oncology and Breast Pathology Section, Hospital Universitari Quirón Dexeus , Barcelona , Spain.
R
R
Fábregas
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
Breast cancer; breast tumour subtypes; neoadjuvant chemotherapy; pathological response; predictive factors